All Stories

  1. Forced oscillatory parameters as predictors of COPD assessment test improvement in untreated COPD patients

    Article • Respiratory Physiology & Neurobiology, February 2022, Elsevier

    Keita Hirai

  2. Mucus Plugs and Small Airway Dysfunction in Asthma, COPD, and Asthma-COPD Overlap

    Article • Allergy Asthma and Immunology Research, January 2022, The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al

    Keita Hirai

  3. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients

    Article • Journal of Asthma, August 2021, Taylor & Francis

    Keita Hirai

  4. Benralizumab treatment may potentially restore the steroid sensitivity

    Article • Allergy, March 2021, Wiley

    Keita Hirai

  5. Oscillometry as a Predictor of Exercise Tolerance in COPD

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, November 2020, Taylor & Francis

    Keita Hirai

  6. Benralizumab restored expression of key molecules involved in steroid-resistance in patients with severe asthma

    Article • September 2020, European Respiratory Society (ERS)

    Keita Hirai

  7. Combined assessment of serum eosinophil-derived neurotoxin and YKL-40 may identify asthma-COPD overlap

    Article • September 2020, European Respiratory Society (ERS)

    Keita Hirai

  8. Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

    Article • Journal of Clinical Medicine, August 2020, MDPI AG

    Keita Hirai

  9. miRNA-15b-5p is a useful biomarker for asthma‐COPD overlap

    Article • Allergy, July 2020, Wiley

    Keita Hirai

  10. High fractional exhaled nitric oxide levels may predict short‐term worsening of respiratory oscillometry in asthma

    Article • Allergy, July 2020, Wiley

    Keita Hirai

  11. Combined assessment of serum eosinophil-derived neurotoxin and YKL-40 may identify Asthma-COPD overlap

    Article • Allergology International, June 2020, Elsevier

    Keita Hirai

  12. Forced Oscillatory Parameters Improved After Benralizumab Treatment in Severe Asthma

    Article • May 2020, American Thoracic Society

    Keita Hirai

  13. Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma

    Article • Allergy, April 2020, Wiley

    Keita Hirai

  14. Annual changes in forced oscillation technique parameters correlate with FEV1 decline in patients with asthma, COPD, and asthma-COPD overlap

    Article • Allergology International, April 2020, Elsevier

    Keita Hirai

  15. Annual change in forced oscillation technique correlates with FEV1 decline in patients with asthma, COPD, and asthma-COPD overlap

    Article • Journal of Allergy and Clinical Immunology, February 2020, Elsevier

    Keita Hirai

  16. Effectiveness of benralizumab in patients with severe asthma

    Article • Journal of Allergy and Clinical Immunology, February 2020, Elsevier

    Keita Hirai

  17. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

    Article • The Pharmacogenomics Journal, November 2019, Springer Science + Business Media

    Keita Hirai

  18. Development of Stratified and Personalized Medicine Based on Pharmacogenomic and Pharmacokinetic Analyses

    Article • YAKUGAKU ZASSHI, October 2019, Pharmaceutical Society of Japan

    Keita Hirai

  19. DIFFERENTIATION OF ASTHMA, COPD, AND ASTHMA-COPD OVERLAP VIA A SIMPLIFIED SPUTUM CELL COUNT METHOD

    Article • CHEST Journal, October 2019, Elsevier

    Keita Hirai

  20. FORCED OSCILLATORY PARAMETERS AS PREDICTORS OF COPD ASSESSMENT TEST IMPROVEMENT IN UNTREATED COPD PATIENTS

    Article • CHEST Journal, October 2019, Elsevier

    Keita Hirai

  21. Forced oscillation technique may identify severe asthma

    Article • September 2019, European Respiratory Society (ERS)

    Keita Hirai

  22. Forced oscillation technique may identify asthma-COPD overlap

    Article • Allergology International, July 2019, Elsevier

    Keita Hirai

  23. Forced Oscillation Technique May Identify Severe Asthma

    Article • The Journal of Allergy and Clinical Immunology In Practice, June 2019, Elsevier

    Keita Hirai

  24. Improved cough- and sputum-related quality of life after initiation of treatment in pulmonary tuberculosis

    Article • Respiratory Investigation, February 2019, Elsevier

    Keita Hirai

  25. Impact of gene expression associated with glucocorticoid-induced transcript 1 (GLCCI1) on severe asthma and future exacerbation

    Article • Biological and Pharmaceutical Bulletin, January 2019, Pharmaceutical Society of Japan

    Keita Hirai

  26. Comparison of the association between circulating vitamin D3 levels and clinical outcomes in patients with asthma and chronic obstructive pulmonary disease: a prospective observational study

    Article • Biological and Pharmaceutical Bulletin, January 2019, Pharmaceutical Society of Japan

    Keita Hirai

  27. The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals

    Article • Clinical Pharmacology & Therapeutics, December 2018, Wiley

    Keita Hirai

  28. Forced oscillatory parameters in reversibility testing as predictors for chronic cough responsive to ICS/LABA

    Article • Annals of Allergy Asthma & Immunology, October 2018, Elsevier

    Keita Hirai

  29. Accuracy of a nomogram for vancomycin in patients who are at risk for augmented renal clearance.

    Article • Therapeutic Drug Monitoring, August 2018, Wolters Kluwer Health

    Keita Hirai

  30. Combined assessment of serum periostin and YKL-40 may identify ACO

    Article • The Journal of Allergy and Clinical Immunology In Practice, July 2018, Elsevier

    Keita Hirai

  31. Time-Dependent Decline in Serum Phenytoin Concentration with Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese

    Article • Therapeutic Drug Monitoring, April 2018, Wolters Kluwer Health

    Keita Hirai

  32. (CCTTT)n repeat polymorphism in NOS2 promoter influenced asthma exacerbation

    Article • Journal of Allergy and Clinical Immunology, March 2018, Elsevier

    Keita Hirai

  33. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

    Article • Supportive Care in Cancer, November 2017, Springer Science + Business Media

    Keita Hirai, Ph.D. Toshinobu Hayashi

  34. Association between pentanucleotide repeat polymorphism in NOS2 promoter and asthma exacerbations

    Article • September 2017, European Respiratory Society (ERS)

    Keita Hirai

  35. Comparable serum periostin levels among a Japanese population with asthma, COPD, and asthma-COPD overlap

    Article • September 2017, European Respiratory Society (ERS)

    Keita Hirai

  36. A clustering approach to identify the asthma-COPD overlap (ACO)

    Article • Clinical & Experimental Allergy, August 2017, Wiley

    Keita Hirai

  37. Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Keita Hirai, Ph.D. Toshinobu Hayashi

  38. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine

    Article • European Journal of Clinical Pharmacology, May 2017, Springer Science + Business Media

    Keita Hirai

  39. Comparative Investigation of the Antiemetic Efficacy of Aprepitant Containing Antiemetic Regimen in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Combination Chemotherapy

    Article • Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), January 2017, Japanese Society of Pharmaceutical Health Care and Sciences

    Keita Hirai

  40. Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients

    Article • Medicine, November 2016, Wolters Kluwer Health

    Keita Hirai

  41. Febrile neutropenia is a risk factor for subtherapeutic concentrations of vancomycin (VCM).

    Article • Therapeutic Drug Monitoring, September 2016, Wolters Kluwer Health

    Keita Hirai

  42. Usefulness of the forced oscillation technique in diagnosing asthma-COPD overlap syndrome

    Article • September 2016, European Respiratory Society (ERS)

    Keita Hirai

  43. Risk factors for hypernatremia in patients with tolvaptan treatment

    Article • European Journal of Clinical Pharmacology, July 2016, Springer Science + Business Media

    Keita Hirai

  44. Febrile neutropenia in pediatric patients: a significant risk factor for augmented renal clearance

    Article • Therapeutic Drug Monitoring, June 2016, Wolters Kluwer Health

    Keita Hirai

  45. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study

    Article • The Pharmacogenomics Journal, May 2016, Nature

    Keita Hirai, Ph.D. Toshinobu Hayashi

  46. Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy

    Article • European Journal of Clinical Pharmacology, January 2016, Springer Science + Business Media

    Keita Hirai

  47. Influence of Genetic Polymorphisms and Concomitant Anxiolytic Doses on Antidepressant Maintenance Doses in Japanese Patients with Depression

    Article • Biological and Pharmaceutical Bulletin, January 2016, Pharmaceutical Society of Japan

    Keita Hirai

  48. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy

    Article • Seizure, December 2015, Elsevier

    Keita Hirai

  49. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis

    Article • Drug Metabolism and Pharmacokinetics, June 2015, Elsevier

    Keita Hirai

  50. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy

    Article • Thrombosis Research, May 2015, Elsevier

    Keita Hirai

  51. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension

    Article • Journal of Pharmaceutical and Biomedical Analysis, February 2014, Elsevier

    Keita Hirai

  52. Influence of CYP4F2 Polymorphisms and Plasma Vitamin K Levels on Warfarin Sensitivity in Japanese Pediatric Patients

    Article • Drug Metabolism and Pharmacokinetics, January 2013, Japanese Society for the Study of Xenobiotics

    Keita Hirai

  53. Antinociceptive Effects of St. John's Wort, Harpagophytum Procumbens Extract and Grape Seed Proanthocyanidins Extract in Mice

    Article • Biological and Pharmaceutical Bulletin, January 2008, Pharmaceutical Society of Japan

    Keita Hirai